Dupixint Investigation

Paul, LLP is investigating potential claims involving the prescription drug Dupixent® (dupilumab). Recent reports and scientific studies suggest a possible link between Dupixent and the development of cutaneous T-cell lymphoma (CTCL), a rare form of cancer affecting the skin and immune system. If you or a loved one used Dupixent and were later diagnosed with CTCL or another T-cell lymphoma, you may have legal rights.

What is Dupixent®?

Dupixent (generic name dupilumab) is a prescription drug developed by Sanofi and Regeneron. Since its FDA approval in 2017, it has been used to treat conditions like:

• Moderate to severe atopic dermatitis (eczema)
• Asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis
• Other type-2 inflammation-related diseases

Dupixent works by blocking two immune-signaling proteins (IL-4 and IL-13), reducing inflammation that causes skin, nasal, respiratory, and other symptoms.

Why is Paul, LLP investigating Dupixint?

Recent scientific studies and medical reports suggest Dupixent may carry a rare but serious risk: cutaneous T-cell lymphoma (CTCL). Some key concerns include:

• Increased risk of diagnosis – Patients treated with Dupixent for eczema, asthma, and similar conditions have been found to have a higher risk of developing CTCL compared to those who did not use Dupixent.
• Delayed or mistaken diagnoses – Many early CTCL symptoms (persistent rash, plaques, itching, etc.) resemble eczema. In some reports, Dupixent may have masked underlying lymphoma or delayed recognition of the disease.
• Worsening disease – Some patients experienced progression of lymphoma symptoms after starting Dupixent.

What’s going on legally?

These issues have led to legal claims, questioning whether Sanofi and Regeneron failed to properly warn patients and healthcare providers about the potential risk of CTCL associated with Dupixent. There are also allegations that these companies allowed patients to continue treatment even as CTCL progressed or could have been suspected. Lawsuits are still in early stages across multiple states.

Who might be affected by Dupixint?

While lawsuits are still in early stages, you may want to consider reaching out to an attorney if you (or a loved one) took Dupixent for eczema, asthma, nasal polyps, or another approved condition and were later diagnosed with CTCL, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma. If you then experienced symptoms that worsened during Dupixent treatment or persisted despite typical therapies, you may be eligible.

Possible Compensation in Dupixint Lawsuits

If a legal claim is successful, you may be able to recover for:

• Past and future medical expenses
• Lost income and reduced earning capacity
• Pain, suffering, and loss of quality of life
• Wrongful death damages in cases involving a loved one’s passing

What You Should Do If You Developed Cancer after Taking Dupixint

If you were diagnosed with cancer after using Dupixent, keep detailed medical records, including prescriptions, start dates, and biopsy results. Speak with your doctor to confirm your diagnosis and whether Dupixent may have contributed. Then consult an experienced attorney as soon as possible—deadlines can be strict. Paul, LLP is reviewing Dupixent claims and offers free case evaluations to help you understand your legal options. Contact us online or call (816) 984-8100 to learn more about how we can help.